Allakos Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 1 of 1 Posts
Allakos Drops After Regeneron Eosinophilic Esophagitis Study Hits Endpoints
Article By: The Fly Tuesday, May 26, 2020 12:17 PM EST
Shares of Allakos are lower after Regeneron Pharmaceuticals announced yesterday that Part A of a Phase 3 trial evaluating Dupixent in patients 12 years and older with eosinophilic esophagitis met both of its co-primary endpoints.
In this article: REGN, ALLK
Read
1 to 1 of 1 Posts